Control of Echinococcus granulosus in Cyprus and comparison with other island models.
A control programme directed against Echinococcus granulosus was introduced into the Republic of Cyprus in 1971. In 1974, this was restricted to the areas controlled by the government of the island. The force used in the 'attack' phase included a major dog control programme. This and other measures led to the rapid 'disappearance' of the parasite and control was terminated in 1985. Subsequent studies during 1993-1996 revealed that the parasite was present in 82 (20%) villages in either dogs or food animals or both and control was re-introduced in the 'consolidation' phase with emphasis on the surveillance of E. granulosus in intermediate hosts, animal movement control and treatment of dogs in 'infected' villages. During these surveys, a major difficulty was found to be in determining whether transmission was autocthonus or introduced by animals from the areas not controlled by the government. Evidence was found to suggest the former was the most likely for the infected animals which had been born and reared far from the dividing line in the government-controlled area. A major contribution of this and other island programmes, such as those in Iceland, New Zealand, Tasmania (Australia) and the Falkland Islands, to an understanding of control planning has been the demonstration that it cannot readily be determined when eradication has been achieved and that once the costly 'attack' phase has been converted into the much more cost-effective 'consolidation' phase this must be maintained indefinitely in that phase if there is cross-border transmission as is likely to be the case in all Continental control programmes.
Economides
P
P
Department of Veterinary Services, Ministry of Agiculture, Natural Resources and Environment, Nicosia, Cyprus. vet.services@cytanet.com.cy
Christofi
G
G
Gemmell
M A
MA
D000818:Animals; D000923:Anticestodal Agents / Q000627:therapeutic use; D001115:Arecoline; D001266:Atlantic Islands / Q000453:epidemiology; D002417:Cattle; D002418:Cattle Diseases / Q000453:epidemiology / Q000517:prevention & control; D003535:Cyprus / Q000453:epidemiology; D004283:Dog Diseases / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D004285:Dogs; D004443:Echinococcosis / Q000453:epidemiology / Q000517:prevention & control / Q000662:veterinary*; D004446:Echinococcus / Q000276:immunology / Q000302:isolation & purification; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D005260:Female; D015511:Goat Diseases / Q000453:epidemiology / Q000517:prevention & control; D006041:Goats; D006801:Humans; D007055:Iceland / Q000453:epidemiology; D009520:New Zealand / Q000453:epidemiology; D010277:Parasympathomimetics; D011223:Praziquantel / Q000627:therapeutic use; D012756:Sheep; D012757:Sheep Diseases / Q000453:epidemiology / Q000517:prevention & control; D013648:Tasmania / Q000453:epidemiology
D000923:Anticestodal Agents; D010277:Parasympathomimetics; D001115:Arecoline; D011223:Praziquantel